INFLARX NV's ticker is IFRX and the CUSIP is N44821101. A total of 39 filers reported holding INFLARX NV in Q2 2023. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $8,352 | +13.0% | 4,800 | 0.0% | 0.00% | – |
| Q1 2024 | $7,392 | -5.5% | 4,800 | 0.0% | 0.00% | – |
| Q4 2023 | $7,824 | -45.3% | 4,800 | 0.0% | 0.00% | – |
| Q3 2023 | $14,304 | -33.2% | 4,800 | 0.0% | 0.00% | – |
| Q2 2023 | $21,408 | +129.9% | 4,800 | 0.0% | 0.00% | – |
| Q1 2023 | $9,312 | -37.4% | 4,800 | 0.0% | 0.00% | – |
| Q4 2022 | $14,880 | +14.5% | 4,800 | 0.0% | 0.00% | – |
| Q3 2022 | $13,000 | +85.7% | 4,800 | 0.0% | 0.00% | – |
| Q2 2022 | $7,000 | -22.2% | 4,800 | 0.0% | 0.00% | – |
| Q1 2022 | $9,000 | -60.9% | 4,800 | 0.0% | 0.00% | – |
| Q4 2021 | $23,000 | +91.7% | 4,800 | 0.0% | 0.00% | – |
| Q3 2021 | $12,000 | +200.0% | 4,800 | +300.0% | 0.00% | – |
| Q2 2021 | $4,000 | -100.0% | 1,200 | -58.6% | 0.00% | – |
| Q1 2021 | $11,310,000 | +102718.2% | 2,900 | +31.8% | 0.00% | – |
| Q4 2020 | $11,000 | +83.3% | 2,200 | +69.2% | 0.00% | – |
| Q3 2020 | $6,000 | -14.3% | 1,300 | -13.3% | 0.00% | – |
| Q2 2020 | $7,000 | – | 1,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,764,888 | $60,571,000 | 13.75% |
| RA Capital Management | 1,967,848 | $67,537,000 | 3.61% |
| Cormorant Asset Management, LP | 1,341,540 | $46,042,000 | 2.99% |
| Redmile Group, LLC | 2,024,900 | $69,495,000 | 2.14% |
| EMORY UNIVERSITY | 90,437 | $3,104,000 | 2.03% |
| Artal Group S.A. | 500,000 | $17,160,000 | 0.45% |
| Birchview Capital, LP | 16,000 | $549,000 | 0.35% |
| Eventide Asset Management | 275,000 | $9,438,000 | 0.35% |
| Rock Springs Capital Management LP | 177,500 | $6,092,000 | 0.22% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,551,959 | $87,583,000 | 0.20% |